Table 1.
Summary of patient characteristics
| Patient characteristic | Value |
|---|---|
| Demographic data | |
| Number of patients (n) | 100 |
| Gender (female/male) | 70 (70)/30 (30) |
| Age (years) | 39.8 (20.7–80.4) |
| Weight (kg) | 70 (50–124) |
| Body mass index ( kg m −2 ) | 24.5 (18.7–41.3) |
| Height (m) | 1.67 (1.52–1.90) |
| Biochemical assessment | |
| ALT (μkat l −1 ) | 0.33 (0.14–1.57) |
| AST (μkat l −1 ) | 0.31 (0.16–0.91) |
| Cr s (μmol l −1 ) | 74 (39–125) |
| CL cr (ml min−1) | 107.6 (40.84–246) |
| Co‐medication | |
| Inducers | |
| Carbamazepine (n) | 4 (4) |
| Oxcarbazepine (n) | 6 (6) |
| Phenytoin (n) | 2 (2) |
| Phenobarbital (n) | 2 (2) |
| Oral contraceptives (n) | 2 (2) |
| Inhibitors | |
| Valproic acid (n) | 13 (13) |
| Sertraline (n) | 2 (2) |
| Other | |
| LTG dose (mg day –1 ) | 200 (50–600) |
| Somatic diseases (Yes/No) | 18 (19)/78 (79) |
| Smokers/Non‐smokers | 17 (22)/59 (78) |
Continuous data are presented as median (range) and categorical data as the number of patients (%). ALT, alanine transaminase; AST, aspartate transaminase; CLcr, Cockroft–Gault estimate of creatinine clearance; Crs, serum creatinine.